Perrigo/$PRGO
1D1W1MYTD1Y5YMAX
Capital at risk
About Perrigo
Perrigo is a pure-play consumer healthcare product manufacturer and distributor. In North America (two-thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. It plays in a number of over-the-counter categories including pain, skincare, women's health, and nutrition. Perrigo also competes in Europe, Australia, and parts of Asia, where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
- Ticker
- $PRGO
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 8,100
- Headquarters
- Dublin, Ireland
- Website
- www.perrigo.com
Perrigo Metrics
BasicAdvanced
$1.9B
-
-$12.49
0.54
$1.16
8.49%
Price and volume
Market cap
$1.9B
Beta
0.54
52-week high
$22.65
52-week low
$9.23
Average daily volume
2.7M
Dividend rate
$1.16
Financial strength
Current ratio
2.324
Quick ratio
1.052
Long term debt to equity
130.511
Total debt to equity
138.183
Interest coverage (TTM)
1.28%
Profitability
EBITDA (TTM)
615.9
Gross margin (TTM)
33.26%
Net profit margin (TTM)
-41.85%
Operating margin (TTM)
6.75%
Effective tax rate (TTM)
-5.62%
Revenue per employee (TTM)
$510,000
Management effectiveness
Return on assets (TTM)
1.98%
Return on equity (TTM)
-48.75%
Valuation
Price to revenue (TTM)
0.458
Price to book
0.75
Price to tangible book (TTM)
-1.38
Price to free cash flow (TTM)
15.197
Free cash flow yield (TTM)
6.58%
Free cash flow per share (TTM)
0.899
Dividend yield (TTM)
8.49%
Forward dividend yield
8.49%
Growth
Revenue change (TTM)
-4.19%
Earnings per share change (TTM)
2,047.94%
3-year revenue growth (CAGR)
-3.62%
10-year revenue growth (CAGR)
-2.47%
3-year earnings per share growth (CAGR)
192.09%
10-year earnings per share growth (CAGR)
5.85%
3-year dividend per share growth (CAGR)
2.86%
10-year dividend per share growth (CAGR)
7.95%
What the Analysts think about Perrigo
Analyst ratings (Buy, Hold, Sell) for Perrigo stock.
Analyst projections of the future price of Perrigo stock.
Bulls say / Bears say
Adjusted diluted EPS of $0.50 beat the $0.39 consensus by $0.11 and GAAP EPS rose to $0.63 from $0.00 a year ago, driving a >20% pre-market jump in shares post-announcement (TradingView News).
Key European brands grew 3.3% and captured 50 basis points of market share in Q2 2026 versus a 0.6% category decline, underscoring the strength of Perrigo’s national-brand portfolio (Roic AI transcript).
Completion of the Dermacosmetics divestiture on April 30, 2026 generated approximately €306 million in net proceeds, which were largely applied to debt reduction, enhancing Perrigo’s financial flexibility and lowering interest expenses (Investing.com).
All In net sales declined 3.2% year-over-year to $1.02 billion and Core net sales fell 3.1%, reflecting persistent softness in core OTC demand and retailer destocking in Q2 2026 (PRNewswire).
Core adjusted gross margin compressed by 250 basis points to 37.0% and Reported gross margin fell 370 basis points to 30.7% in Q2 2026, as lower production volumes and unfavorable mix outweighed limited tariff recoveries (PRNewswire).
Continuing strategic reviews of the Infant Formula and Oral Care businesses in Q2 2026 highlight management’s consideration of divesting core segments, introducing execution risk and potential loss of future revenue streams (PRNewswire).
Data summarised monthly by Lightyear AI. Last updated on 1 Sept 2026.
Perrigo Financial Performance
Revenues and expenses
Perrigo Earnings Performance
Company profitability
Upcoming events
Perrigo News
AllArticlesVideos
Funds containing Perrigo
AllEURGBPUSD
Fund name | Fund size | $PRGO weighting |
|---|---|---|
SPDR S&P US Dividend Aristocrats€SPYD | €3.3B | 0.08% |
SPDR S&P US Dividend Aristocrats£USDV | £2.8B | 0.08% |
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.08% |
iShares S&P Small Cap 600£ISP6 | £2.4B | 0.08% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.06% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.